Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
Epidemiology of Classical Hodgkin Lymphoma and Its Association with Epstein Barr Virus in Northern China
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0021152
document
Background: The incidence of classical Hodgkin lymphoma (cHL) and its association with Epstein-Barr virus (EBV) varies significantly with age, sex, ethnicity and geographic location. This is the first report on epidemiological features of cHL patients from Northern regions of China. These features are compared to data from a previously published Dutch cHL population. Methodology/Principal Findings: 157 cHL patients diagnosed between 1997 and 2008 in the North of China were included after histopathological re-evaluation. The Dutch population-based cohort consisted of 515 cHL patients diagnosed between 1987 and 2000. EBV...
Xin Huang, Ilja Nolte, Zifen Gao, Hans Vos, Bouke Hepkema, Sibrand Poppema, Anke van den Berg, Arjan Diepstra
A chronic obstructive pulmonary disease related signature in squamous cell lung cancer
Published in: Lung Cancer
Access to document
10.1016/j.lungcan.2010.08.014
The epidemiological relationship between squamous cell lung cancer (SCC) and chronic obstructive pulmonary disease (COPD), both smoking-related diseases, suggests that they have also a genetic basis. We compared 35 SCC patients with and without COPD with whole-genome gene expression profiles of laser microdissected tissue. Validation of differential expression was performed for 25 genes using quantitative (q)RT-PCR. Subsequently, we performed array-based CGH on the same tumor samples. We found that 374 probes were differentially expressed in SCC from patients with and without COPD. Forty-four probes were derived from genes...
Mirjam C. Boelens, Adam M. Gustafson, Dirkje S. Postma, Klaas Kok, Gerben van der Vries, Pieter van der Vlies, Avrum Spira, Marc E. Lenburg, Marie Geerlings, Hannie Sietsma, Wim Timens, Anke van den Berg, Harry J. M. Groen
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Published in: Nature
Access to document
10.1038/nature09754
Chromosomal translocations are critically involved in the molecular pathogenesis of B-cell lymphomas, and highly recurrent and specific rearrangements have defined distinct molecular subtypes linked to unique clinicopathological features(1,2). In contrast, several well-characterized lymphoma entities still lack disease-defining translocation events. To identify novel fusion transcripts resulting from translocations, we investigated two Hodgkin lymphoma cell lines by whole-transcriptome paired-end sequencing (RNA-seq). Here we show a highly expressed gene fusion involving the major histocompatibility complex (MHC) class II transactivator CIITA (MHC2TA) in KM-H2 cells. In a subsequent evaluation of 263 B-cell...
Christian Steidl, Sohrab P. Shah, Bruce W. Woolcock, Lixin Rui, Masahiro Kawahara, Pedro Farinha, Nathalie A. Johnson, Yongjun Zhao, Adele Telenius, Susana Ben Neriah, Andrew McPherson, Barbara Meissner, Ujunwa C. Okoye, Arjan Diepstra, Anke van den Berg, Mark Sun, Gillian Leung, Steven J. Jones, Joseph M. Connors, David G. HuntsmanKerry J. Savage, Lisa M. Rimsza, Douglas E. Horsman, Louis M. Staudt, Ulrich Steidl, Marco A. Marra, Randy D. Gascoyne
A genome-wide association study of Hodgkin’s lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)
Published in: Nature Genetics
Access to document
10.1038/ng.696
To identify susceptibility loci for classical Hodgkin’s lymphoma (cHL), we conducted a genome-wide association study of 589 individuals with cHL (cases) and 5,199 controls with validation in four independent samples totaling 2,057 cases and 3,416 controls. We identified three new susceptibility loci at 2p16.1 (rs1432295, REL, odds ratio (OR) = 1.22, combined P = 1.91 x 10(-8)), 8q24.21 (rs2019960, PVT1, OR = 1.33, combined P = 1.26 x 10(-13)) and 10p14 (rs501764, GATA3, OR = 1.25, combined P = 7.05 x 10(-8)). Furthermore, we confirmed the role of...
Victor Enciso-Mora, Peter Broderick, Yussanne Ma, Ruth F. Jarrett, Henrik Hjalgrim, Kari Hemminki, Anke van den Berg, Bianca Olver, Amy Lloyd, Sara E. Dobbins, Tracy Lightfoot, Flora E. van Leeuwen, Asta Foersti, Arjan Diepstra, Annegien Broeks, Jayaram Vijayakrishnan, Lesley Shield, Annette Lake, Dorothy Montgomery, Eve RomanAndreas Engert, Elke Pogge von Strandmann, Katrin S. Reiners, Ilja M. Nolte, Karin E. Smedby, Hans-Olov Adami, Nicola S. Russell, Bengt Glimelius, Stephen Hamilton-Dutoit, Marieke de Bruin, Lars P. Ryder, Daniel Molin, Karina Meden Sorensen, Ellen T. Chang, Malcolm Taylor, Rosie Cooke, Robert Hofstra, Helga Westers, Tom van Wezel, Ronald van Eijk, Alan Ashworth, Klaus Rostgaard, Mads Melbye, Anthony J. Swerdlow, Richard S. Houlston